


PRO METHUEUS

LIFE TECHNOLOGIES

We enable at-scale, commercial production of high-quality organoids in microgravity, to improve biological testing and regenerative medicine



Life sciences challenges

\$1.4bn

Average estimated cost of developing a successful drug

90%

Of drug candidates fail in clinical trials

100MM

Est. number of animals sacrificed p.a.



106k


People(U.S.) are waiting for a life saving organ transplant



17

Avg. number of people who die per day while on the waiting list

Prometheus Organoids



Superior and more ethical model than animal testing



Eliminates inviable drug candidates at the preclinical stage



Enables personalized and precision medicine



Solve rejection issues in regenerative (incl. transplantation) medicine



FDA MODERNIZATION ACT ALLOWS SUBSTITUTION OF ANIMAL MODELS

A BILL

To allow for alternatives to animal testing for purposes of drug and biological product applications.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the “FDA Modernization Act 2.0”.

SEC. 2. ALTERNATIVES TO ANIMAL TESTING.

(a) IN GENERAL.—Section 505 of the Federal Food, Drug, and Cosmetic Act ([21 U.S.C. 355](#)) is amended—

(1) in subsection (i)—

(A) in paragraph (1)(A), by striking “preclinical tests (including tests on animals)” and inserting “nonclinical tests”; and

(B) in paragraph (2)(B), by striking “animal” and inserting “nonclinical tests”; and

(2) after subsection (y), by inserting the following:

“(z) NONCLINICAL TEST DEFINED.—For purposes of this section, the term ‘nonclinical test’ means a test conducted in vitro, in silico, or in chemico, or a non-human in vivo test that occurs before or during the clinical trial phase of the investigation of the safety and effectiveness of a drug, and may include animal tests, or non-animal or human biology-based test methods, such as cell-based assays, microphysiological systems, or bioprinted or computer models.”.



PHARMA HAS TAKEN NOTICE

nature reviews drug discovery

Explore content ▾ About the journal ▾ Publish with us ▾

[nature](#) > [nature reviews drug discovery](#) > [an audience with](#) > article







AN AUDIENCE WITH | 16 February 2023

Mini-organs attract big pharma

Hans Clevers, head of Pharma Research & Early Development: for organoids in drug discovery and development.

FIERCE Biotech Research Biotech Medtech CRO Special Reports Trending Topics Podcasts

BIOTECH

Roche creates organoid research institute to shake up drug discovery and development

By Nick Paul Taylor • May 4, 2023 07:00am

Roche organoid




TARGET MARKETS

Biological testing

- Pharmaceutical Companies
- Research Institutions
- Clinics/Hospitals involved in regenerative medicine

Regenerative medicine

- Clinics/Hospitals involved in regenerative medicine



Source: Grandview Research



Prometheus organoids produced in microgravity show significant advantages over traditional organoids

Traditional Organoids

- Requires **foreign materials**
- Unwanted cellular reactions
- **Rejection** issues in regenerative medicine
- **Not uniform** quality
- Own organoid development is resource intensive

Prometheus Organoids


- **No scaffolds/matrices** required
- **Better differentiation** in microgravity
- **Uniform** quality
- **Customized sizes** up to 1mm




Superior differentiation of organoid in microgravity

Ground
Control

Cartilage (Azan)





Liver (HE)



Ground control organoids contain large areas of connective tissue (pale colored; ←).

Space



Production in space results in a significant better and more homogeneous differentiation.



TAKING ADVANTAGE OF UPCOMING CAPACITY

≈20

Upcoming commercial microgravity platforms



4

Microgravity platforms in which Prometheus affiliates are shareholders

\$30K

Commercial target price for launch & return of 1kg of mass



BUSINESS MODEL


REVENUE DRIVERS

- Organoids for biological testing
⇒ sell by unit / plate
- Regenerative medicine therapies
⇒ by therapy (with a partner)
- Personalized biobanking
⇒ custom packages

COST OF SALES DRIVERS

- Raw materials (cells, media)
- Labor
- Spaceflight

CAPEX – low capital intensity!



*Notes:

- Reflects space organoid business line only.
- Does not include ancillary products and services, terrestrial organoids, personalized and regenerative medicine products.
- 2025 revenue: our priority is to fly with beta-testing commercial customers, not to maximize revenue at this point.



Our team combines life sciences, space and business expertise



Raphael Roettgen, CFA
Co-founder & CEO

Space business, investment and entrepreneurial expertise



Swantje Christoffel, PhD
Head of R&D

Experienced scientist known to our founders



Célia Metry
Research Scientist

Experienced scientist known to our founders



Cora Thiel, PhD
Co-founder & Chief Scientific Advisor

Distinguished bio academic - developed our technology



Victoria Rendon
R&D Liaison (Strasbourg)

Life sciences & Space background



TBD
Head of Sales - to be recruited

Experience in commercial role at pharma/biotech company



Aaron Kemmer
Entrepreneur-in-Residence

Pioneered in-space manufacturing as founder of Made In Space (acquired by Redwire)



Catarina Santos, PhD MBA
Commercial Advisor

Senior commercial executive in the pharma sector with 15 years' experience



Justin Karl, PhD
Chief Space Advisor

Decades of microgravity experimentation and payload experience



Liliana Layer, PhD
Co-founder, Scientific Advisor & Shareholder

Bio academic - worked with Prof. Dr. Ullrich & Dr. Thiel on our space missions




Prof. Oliver Ullrich, PhD MD
Co-founder, Senior Scientific Advisor & Shareholder

Distinguished bio academic - developed our technology



OUR EXPERTISE POSITIONS US BE AMONG THE LEADERS IN THIS MARKET



BUSINESS MILESTONES



FUNDING ROUND

- Up to CHF2MM (600k done)
- From value-added VCs and/or family offices and angels
- Significant non-dilutive funding potential
 - >CHF300k won
 - Will apply for >CHF1MM in 2024/25
- Use of funds
 - Hiring business development, R&D staff
 - Set up R&D lab
 - Commercial pathfinder mission
 - Approx. 20 months' runway

